Current Report Filing (8-k)
April 15 2014 - 1:12PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event)
April 15, 2014; (April 10, 2014)
GUIDED THERAPEUTICS, INC.
(Exact Name of Registrant as Specified
in Its Charter)
|
|
|
Delaware |
0-22179 |
58-2029543 |
(State or Other Jurisdiction of |
(Commission File Number) |
(IRS Employer Identification No.) |
Incorporation) |
|
|
|
|
5835 Peachtree Corners East, Suite D
Norcross, Georgia
(Address of Principal Executive Offices) |
30092
(Zip Code) |
Registrant's Telephone Number, Including Area
Code: (770) 242-8723
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ] |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
[ ] |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
[ ] |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
[ ] |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
|
Section 7.01 (Regulation FD Disclosure)
On
April 10, 2014, the registrant publicly issued a press release announcing that the registrant has scheduled a May 8,
2014 meeting with the U.S. Food and Drug Administration to discuss the premarket approval application for the LuViva® Advanced
Cervical Scan, as more fully described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which
information is incorporated herein by reference.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits.
|
|
Number |
Exhibit |
|
|
99.1 |
Press Release dated April 10, 2014 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
GUIDED THERAPEUTICS, INC. |
|
|
|
|
|
|
By: |
/s/ Gene Cartwright |
|
|
|
Gene Cartwright |
|
|
|
Chief Executive Officer |
|
Date: April 15, 2014 |
|
|
|
Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
From Oct 2024 to Nov 2024
Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
From Nov 2023 to Nov 2024